Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Eluminex Acquires Global Rights to Therapy for Rare Genetic Blindness

publication date: Jan 21, 2022

Suzhou Eluminex Biosciences, an ophthalmology company, acquired global rights to a novel oral therapy for childhood blindness and night blindness in early dry AMD from Seattle's Retinagenix. The candidate, zuretinol acetate, is being developed to treat rare forms of childhood blindness in patients with Leber's Congenital Amaurosis or Retinitis Pigmentosa caused by mutations of the RPE65 or LRAT gene. Zuretinol is scheduled to start pediatric Phase IIb/III trial later in 2022. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital